Compugen FROM CODE TO CURE

Computational Identification, Functional Characterization and Antibody Blockade of a New Immune Checkpoint in the TIGIT Family of Interacting Molecules

JOHN HUNTER SITC 2016 ANNUAL MEETING

www.cgen.com

Presenter Disclosure Information


The following relationships exist related to this presentation:

Compugen – Employee with stock options



THE SEARCH FOR NEW IMMUNE CHECKPOINTS


Addressing Non-responsive Patient Populations



- Therapeutics targeting immune checkpoints have revolutionized cancer treatment
 - Durable responses in a subset of patients
 - Expansion of responsive populations with combination treatment
- Majority of patients don't derive lasting benefit
 - New treatment options needed



PVRIG (CGEN-15029) FUNCTIONAL GENE STRUCTURE MATCHES KNOWN IMMUNE CHECKPOINT RECEPTORS




Use of 'Functional Homology' in absence of sequence similarity based on exon size, phase, and functional elements within exons






PVRIG EXHIBITS TUMOR EXPRESSION CHARACTERISTICS CONSISTENT WITH T-CELL RECEPTOR CHECKPOINTS

Normal RNA expression restricted to lymphocytes; higher expression in solid tumors




Zcompugen




PVRIG EXPRESSION ON NAÏVE PBMC SUBSETS

PVRIG EXPRESSION IS INDUCED FOLLOWING T-CELL ACTIVATION AND ELEVATED ON T_{EMRA} AND T_{EM} CELLS




PVRIG EXPRESSION IS UPREGULATED IN HUMAN AND MOUSE TUMORS



Zcompugen

Erez and Abramovitz, Tel Aviv Univ.


INHIBITION OF T-CELL ACTIVATION BY PVRIG OVEREXPRESSION



Fcompugen


IDENTIFICATION OF PVRL2 AS THE LIGAND FOR PVRIG

RETROGENIX CELL MICROARRAY



Żcompugen


CONFIRMATION OF PVRIG (CD112R) BINDING TO PVRL2 (CD112)



Specific binding of PVRL2 to receptor PVRIG was confirmed by SPR, ELISA and FACS

Žcompugen


PVRL2 IS A LIGAND IN THE DNAM-1/TIGIT IMMUNE CHECKPOINT AXIS






Martinet & Smyth, 2015 (modified)

DEVELOPMENT OF COM701: A HIGH AFFINITY PVRIG ANTAGONIST




- Human phage display and standard hybridoma
- Antibodies screened for:
 - High affinity (K_D < 1nM)
 - Ability to block PVRIG/PVRL2 binding
 - In vitro enhancement of T-cell activation
- COM701 selected as therapeutic lead
 - IND anticipated in 2017

ANTAGONIST PVRIG ANTIBODIES INCREASE CD4⁺ T-CELL PROLIFERATION







ANTI-PVRIG BLOCKING ANTIBODIES ENHANCE TIL ACTIVATION




MART-1/624-mel





Fcompugen

COMBINING PVRIG AND TIGIT BLOCKADE INCREASES TIL ACTIVATION







COMBINING PVRIG AND TIGIT BLOCKADE RESULTS IN ENHANCED ACTIVATION OF CMV REACTIVE CD8⁺ CELLS

+104%

CONTON * SHITTEET







Fcompugen

GENERATION OF HIGH AFFINITY ANTI-mPVRIG ANTIBODIES FOR IN VIVO TESTING

Rat anti-mPVRIG antibodies generated through DNA immunization

High affinity mPVRIG/mPVRL2 blockers selected for in vivo testing






Blockade of mPVRIG-Fc binding to B16-F10 cells


Fcompugen

PVRIG BLOCKING ANTIBODIES REDUCE TUMOR GROWTH AND INCREASE SURVIVAL IN COMBINATION WITH PD1 PATHWAY BLOCKADE




Fcompugen

PVRIG BLOCKING ANTIBODIES REDUCE TUMOR GROWTH IN COMBINATION WITH PD1 PATHWAY BLOCKADE



MC38 TUMOR GROWTH IS REDUCED IN PVRIG KNOCKOUT MICE



Fompugen

SUMMARY

- PVRIG was identified as a novel immune checkpoint on T cells that binds the DNAM-1 ligand PVRL2
- Antibody antagonism of PVRIG enhances T-cell activation in vitro, and in combination with PD-L1 inhibition results in decreased tumor growth in vivo
- Compugen has generated a high affinity PVRIG antagonistic antibody, COM701, that is currently in preclinical development
- The combined data demonstrates the utility of targeting PVRIG in addition to other B7 family checkpoints for the treatment of cancer



PLEASE VISIT POSTER 450 FOR MORE INFORMATION





ACKNOWLEDGEMENTS

COMPUGEN

- Ofer Levy
- Chris Chan
- Eran Ophir
- Lance Stapleton
- Ilan Vaknin
- Ling Leung
- Sandeep Kumar
- Meir Azulay
- Zoya Alteber
- Kathryn Logronio

- Tal Fridman-Kfir
- Sara Whelan
- Yakir Vaknin
- Maya Kotturi
- Einav Safyon
- Kyle Hansen
- Ran Salomon
- Shirley Greenwald
- Hsin-Yuan Cheng
- Lennard Dalit

- Liat Dassa
- Amir Toporik
- Gady Cojocaru
- Ayelet Chajut
- Arthur Machlenkin
- Spencer Liang
- Yossi Gozlan
- Mark White
- Zurit Levine

Johns Hopkins University

- Sudipto Ganguly
- Benjamin Murter
- Xiaoyu Pan
- Charles Drake
- Drew Pardoll

Bar-Ilan University

Cyrille Cohen

Tel Aviv University

- Neta Erez
- Lilach Abramovitz

Zcompugen